Novartis’ Blockbuster Hopeful Leqvio Faces Perils Of Medicare’s Pricing Policy On Small Molecules

 
• By Cathy Kelly

Medicare’s pending price negotiation program could impact the longevity of the Part B cholesterol drug Leqvio. Novartis CEO Vas Narasimhan notes the upcoming redesign of the Part D benefit could boost pricing pressure on Kisqali.

Biopharma Companies Evaluating The Challenges Ahead In Medicare • Source: Shutterstock

More from Pricing Debate

More from Market Access